These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 32079617)

  • 1. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
    Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
    Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
    Gulley JL; Schlom J; Barcellos-Hoff MH; Wang XJ; Seoane J; Audhuy F; Lan Y; Dussault I; Moustakas A
    Mol Oncol; 2022 Jun; 16(11):2117-2134. PubMed ID: 34854206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status.
    Gameiro SR; Strauss J; Gulley JL; Schlom J
    Exp Biol Med (Maywood); 2022 Jul; 247(13):1124-1134. PubMed ID: 35473390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiolabelling and preclinical characterization of
    Burvenich IJG; Goh YW; Guo N; Gan HK; Rigopoulos A; Cao D; Liu Z; Ackermann U; Wichmann CW; McDonald AF; Huynh N; O'Keefe GJ; Gong SJ; Scott FE; Li L; Geng W; Zutshi A; Lan Y; Scott AM
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3075-3088. PubMed ID: 33608805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer.
    Yoo C; Oh DY; Choi HJ; Kudo M; Ueno M; Kondo S; Chen LT; Osada M; Helwig C; Dussault I; Ikeda M
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
    Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J
    Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β.
    Lan Y; Zhang D; Xu C; Hance KW; Marelli B; Qi J; Yu H; Qin G; Sircar A; Hernández VM; Jenkins MH; Fontana RE; Deshpande A; Locke G; Sabzevari H; Radvanyi L; Lo KM
    Sci Transl Med; 2018 Jan; 10(424):. PubMed ID: 29343622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa.
    Ozawa Y; Hicks KC; Minnar CM; Knudson KM; Schlom J; Gameiro SR
    Oncoimmunology; 2021 May; 10(1):1915561. PubMed ID: 33996267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
    Barlesi F; Isambert N; Felip E; Cho BC; Lee DH; Peguero J; Jerusalem G; Penel N; Saada-Bouzid E; Garrido P; Helwig C; Locke G; Ojalvo LS; Gulley JL
    Oncologist; 2023 Mar; 28(3):258-267. PubMed ID: 36571770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy.
    Tschernia NP; Gulley JL
    BioDrugs; 2022 Mar; 36(2):153-180. PubMed ID: 35353346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
    Cho BC; Daste A; Ravaud A; Salas S; Isambert N; McClay E; Awada A; Borel C; Ojalvo LS; Helwig C; Rolfe PA; Gulley JL; Penel N
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32641320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
    Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.
    Paz-Ares L; Kim TM; Vicente D; Felip E; Lee DH; Lee KH; Lin CC; Flor MJ; Di Nicola M; Alvarez RM; Dussault I; Helwig C; Ojalvo LS; Gulley JL; Cho BC
    J Thorac Oncol; 2020 Jul; 15(7):1210-1222. PubMed ID: 32173464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer.
    Gatti-Mays ME; Gameiro SR; Ozawa Y; Knudson KM; Hicks KC; Palena C; Cordes LM; Steinberg SM; Francis D; Karzai F; Lipkowitz S; Donahue RN; Jochems C; Schlom J; Gulley JL
    Front Oncol; 2020; 10():581801. PubMed ID: 33747894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial.
    Spira A; Wertheim MS; Kim EJ; Tan B; Lenz HJ; Nikolinakos P; Rich PL; Jehl G; Machl A; Ito R; Gulley JL; Kopetz S
    Oncologist; 2023 Feb; 28(2):e124-e127. PubMed ID: 36576431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual targeting of TGF-β and PD-L1 inhibits tumor growth in TGF-β/PD-L1-driven colorectal carcinoma.
    Khalili-Tanha G; Fiuji H; Gharib M; Moghbeli M; Khalili-Tanha N; Rahmani F; Shakour N; Maftooh M; Hassanian SM; Asgharzadeh F; Shahidsales S; Anvari K; Mozafari MR; Ferns GA; Batra J; Giovannetti E; Khazaei M; Avan A
    Life Sci; 2023 Sep; 328():121865. PubMed ID: 37336360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy - Updated.
    Karami Z; Mortezaee K; Majidpoor J
    Int Immunopharmacol; 2023 Sep; 122():110648. PubMed ID: 37459782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.
    Strauss J; Gatti-Mays ME; Cho BC; Hill A; Salas S; McClay E; Redman JM; Sater HA; Donahue RN; Jochems C; Lamping E; Burmeister A; Marté JL; Cordes LM; Bilusic M; Karzai F; Ojalvo LS; Jehl G; Rolfe PA; Hinrichs CS; Madan RA; Schlom J; Gulley JL
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33323462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort.
    Tan B; Khattak A; Felip E; Kelly K; Rich P; Wang D; Helwig C; Dussault I; Ojalvo LS; Isambert N
    Target Oncol; 2021 Jul; 16(4):435-446. PubMed ID: 34009501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.